Biotech raises $11m to advance regenerative osteoarthritis drug into Phase 3

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Doron Therapeutics claims a single injection of its drug can deliver improvements in knee pain and function, with long-lasting effects.

Clinical stage biotech Doron Therapeutics has successfully raised $11 million in a Series A funding round to advance its work in degenerative musculoskeletal conditions. The funding is intended to allow the company to commence a Phase 3 clinical trial of its lead program, MOTYS, an intra-articular biologic drug for the treatment of symptomatic knee osteoarthritis (OA).

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3534

Doron Therapeutics

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Doron Therapeutics is a clinical-stage biotechnology company developing regenerative biologic therapies for degenerative musculoskeletal conditions. The company's lead candidate, MOTYS (PTP-001), is an intra-articular biologic derived from placental tissue and classified as a Regenerative Medicine Advanced Therapy (RMAT), currently in Phase 3 clinical development for symptomatic knee osteoarthritis. MOTYS operates through a multifactorial mechanism targeting inflammation reduction, cartilage degeneration prevention, and tissue regeneration. The company is advancing its therapeutic pipeline with the goal of restoring mobility and improving quality of life for patients with joint-related degenerative conditions.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE